http://www.washingtonpost.com/wp-dyn/articles/A54906-2001Sep6.html
New
Vaccines May Keep HIV in Check
Remedies Don't Prevent Infection but Seem to
Preserve Lab Animals' Health
|
|
|
By David Brown
Washington Post Staff Writer
Friday, September 7, 2001; Page A02
The vaccines, delivered by injection or, in one case, by nasal spray, work
by stimulating the immune system so it can keep the AIDS virus in check. The
effect has lasted for more than a year and a half, but it is not known whether
it will continue indefinitely or work in people.
Such vaccines fall well short of the goal of developing a preventive HIV
vaccine similar to the ones that exist for measles, mumps, tetanus and numerous
other diseases. Nevertheless, they could prove useful.
"If we had a vaccine that did nothing else but contain infection, could
it have an important effect on the epidemic?" asked Gary J. Nabel, head of
the AIDS vaccine research center at the National Institutes of Health.
"The answer is yes."
Such a vaccine would have two benefits. It would preserve the health of
newly infected people. By lowering the amount of virus in the bloodstream, it
would also make a person less able to transmit the infection to someone else.
Reducing virus transmission would alone have a huge effect on the epidemic.
In one study, John N. Rose and Nina F. Rose of the Yale University School of
Medicine, and scientists from several other institutions, used as a vaccine a
weakened form of the vesicular stomatitis virus (VSV) into which pieces of AIDS
virus genes had been stitched. VSV causes a nonfatal infection in livestock and
occasionally infects human beings, where it causes flu-like symptoms.
The vaccine was given multiple times to seven rhesus monkeys by a
combination of oral drops, intrasal drops and injections. Eight other monkeys
got no vaccine. All the animals were then injected with the AIDS virus.
All became infected, and seven of the eight control monkeys developed AIDS. The
vaccinated monkeys all showed a drop in CD4 cells -- a key gauge of immune
system health -- but the decline was much less than that seen in the other
animals. The concentration of human immunodeficiency virus in the vaccinated
animals' blood was also much less. Most important, the animals have remained
healthy for as long as 11 months, so far.
In a second study, Dan H. Barouch of Harvard Medical School and colleagues
at several other institutions used for their vaccine a piece of DNA that
encodes two genes from the AIDS virus. Along with this vaccine, they injected
the animals with the gene for interleukin-2, a hormone-like substance that
helps stimulate immunity. A group of control animals got no vaccine.
As before, all animals were exposed to the AIDS virus, and all became
infected. Nearly two years later, three-quarters of the control animals were
dead. None of the vaccinated animals was ill, and all had normal numbers of CD4
cells.
In a third study, researchers at the Yerkes Primate Research Center in
Atlanta and two other places used as a vaccine a virus called vaccinia into
which HIV genes had been placed. After being intentionally infected, 19 out of
20 rhesus monkeys that got a high dose of the vaccine were able to suppress the
AIDS virus to below detectable levels. That's the goal for human HIV patients
who are taking triple antiviral therapy.
All these vaccines work by stimulating "cell-mediated immunity,"
which is one of the two main arms of the immune system. The other is immunity
arising from the action of antibodies, which are molecules that target
microbial invaders, stick to them and allow other cells to engulf and kill
them.
Molecules on the surface of viruses and bacteria stimulate the body to
produce antibodies specifically designed to attack the molecules. The problem
is that, for various reasons, HIV's surface molecules don't stimulate antibody
production very well. The molecules are also constantly changing in small but
important ways, which compounds the problem.
It's unlikely -- but not impossible -- that a preventive AIDS vaccine that
doesn't force the body to make large quantities of very powerful anti-HIV
antibodies can be developed. Researchers at a California biotechnology company,
Maxygen Inc., described today a novel strategy for finding such a trigger.
Company scientists are cutting and splicing the genes that encode the
proteins covering the surface of the AIDS virus. The technique is called
"molecular breeding," or "directed molecular evolution,"
and it attempts to speed up what might eventually happen by chance -- the
emergence of an AIDS virus whose surface proteins readily stimulate the immune
system. Such surface proteins -- or the genes for them -- might be good
candidates for a vaccine that is able to stimulate antibody production.
The presentations were part of the AIDS Vaccine 2000 meeting, which will run
through Saturday.
© 2001
The Washington Post Company
ALL INFORMATION, DATA,
AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR
OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING
MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN
IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN
CONSULTATION WITH YOUR HEALTH CARE PROVIDER.